A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism-Reference-Cited by-同舟云学术

A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism

Published:2019-05-08 Issue:491 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Parker Karen J.¹^ORCID,Oztan Ozge¹^ORCID,Libove Robin A.¹,Mohsin Noreen¹,Karhson Debra S.¹^ORCID,Sumiyoshi Raena D.¹^ORCID,Summers Jacqueline E.¹^ORCID,Hinman Kyle E.¹^ORCID,Motonaga Kara S.²^ORCID,Phillips Jennifer M.¹^ORCID,Carson Dean S.¹,Fung Lawrence K.¹^ORCID,Garner Joseph P.¹³^ORCID,Hardan Antonio Y.¹

Affiliation:

1. Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, USA.

2. Department of Pediatrics, Stanford University, Stanford, CA 94305, USA.

3. Department of Comparative Medicine, Stanford University, Stanford, CA 94305, USA.

Abstract

Intranasal delivery of the neuropeptide vasopressin improves social abilities in children with autism spectrum disorder.

Funder

National Institute of Mental Health

Autism Speaks

Eunice Kennedy Shriver National Institute of Child Health and Human Development

Stanford’s Department of Psychiatry

The Teresa and Charles Michael Endowed Fund for Autism Research and Education